SetPoint Medical has recently secured $140 million in private financing to advance the commercial rollout of its SetPoint System, marking a major milestone in neuroimmune therapy for rheumatoid arthritis (RA). This funding underscores strong investor confidence in pioneering neuromodulation approaches to treating chronic autoimmune conditions, says GlobalData.
The SetPoint System targets the body’s neural pathways to modulate the immune response, offering a novel, non-pharmacological therapy that could significantly reduce reliance on traditional drugs such as biologics and immunosuppressants. By directly engaging the neuroimmune axis, SetPoint aims to deliver precision therapy that can adapt dynamically to an individual’s disease activity.
Graysen Vigneux, Medical Analyst at GlobalData, comments, “The funding raised by SetPoint Medical reflects growing enthusiasm for neuromodulation-based therapies in autoimmune disease management. As treatment paradigms shift toward precision and personalisation, neuromodulation presents a compelling complement, or alternative, to conventional pharmacotherapy.”
Neuroimmune modulation represents a fast-emerging frontier in treating inflammatory diseases by manipulating neural circuits to control immune system behaviour. SetPoint’s technology leverages insights into vagus nerve stimulation to attenuate pro-inflammatory signalling, a strategy that aligns with the increasing interest in bioelectronic medicine.
The funding secured by SetPoint is earmarked to support regulatory and clinical development, scale up manufacturing capabilities, expand commercial infrastructure, including reimbursement strategies and provider education, and fuel strategic partnerships with biopharma and healthcare institutions.
Vigneux adds, “With the funding, SetPoint is well-positioned not only to bring its neuroimmune platform to market but also to catalyse broader acceptance of bioelectronic medicine in autoimmune care. By accelerating both regulatory and go-to-market efforts, the funding propels SetPoint toward making its neuroimmune therapy accessible to patients, potentially transforming the RA treatment landscape by offering a durable, device-based solution.”